Growth Metrics

Integra Lifesciences Holdings (IART) Short term Debt (2016 - 2026)

Integra Lifesciences Holdings' Short term Debt history spans 15 years, with the latest figure at $574.6 million for Q2 2025.

  • On a quarterly basis, Short term Debt rose 2272.63% to $574.6 million in Q2 2025 year-over-year; TTM through Jun 2025 was $574.6 million, a 2272.63% increase, with the full-year FY2024 number at $33.9 million, changed N/A from a year prior.
  • Short term Debt hit $574.6 million in Q2 2025 for Integra Lifesciences Holdings, roughly flat from $573.9 million in the prior quarter.
  • Over the last five years, Short term Debt for IART hit a ceiling of $574.6 million in Q2 2025 and a floor of $4.8 million in Q2 2023.
  • Historically, Short term Debt has averaged $102.5 million across 5 years, with a median of $45.0 million in 2021.
  • Biggest five-year swings in Short term Debt: tumbled 90.43% in 2023 and later surged 2862.06% in 2025.
  • Tracing IART's Short term Debt over 5 years: stood at $45.0 million in 2021, then fell by 15.28% to $38.1 million in 2022, then tumbled by 74.59% to $9.7 million in 2023, then surged by 250.02% to $33.9 million in 2024, then surged by 1594.77% to $574.6 million in 2025.
  • Business Quant data shows Short term Debt for IART at $574.6 million in Q2 2025, $573.9 million in Q1 2025, and $33.9 million in Q4 2024.